AcelRx announces dosing of first individual in pivotal ARX-04 Phase 3 study for treatment of acute pain AcelRx Pharmaceuticals, Inc. , , a specialty pharmaceutical company focused on the advancement and commercialization of innovative treatments for the treating acute pain, reported dosing of the 1st affected person in the pivotal Phase 3 research of ARX-04 today. ARX-04 is a noninvasive, single-make use of 30 mcg sufentanil sublingual tablet in a disposable, pre-filled, single-dose applicator pharmacy . This scholarly research, SAP301, is certainly a multi-center, double-blind, placebo-controlled study which will evaluate the safety and efficacy of ARX-04 vs.
One band of individuals was asked to create about what would happen to their body once they die, and the control group was asked to create about having dental pain, an unpleasant but not existentially distressing thought. All of the participants were after that asked to learn an arrest report in regards to a prostitute, and to established the total amount for bail. An interview with Professor Lesley JonesAdvances in whole mount mind imaging: an interview with Patrick Myles, President, Huron Digital PathologyCharles Bonnet syndrome: an interview with Dr. Dominic ffytche As expected Just, the control group that wrote on the subject of dental pain – who weren't made to feel an existentialist threat – gave low bail amounts relatively, no more than $300.